A minimalist version on the treatment of arterial hypertension. Antihypertensive treatment schemes;Una versión minimalista sobre el tratamiento de la hipertensión arterial. Esquemas de tratamiento antihipertensor

Revista Mexicana de Cardiologia

Volumn 19, Issue 1, 2008, Pages 3-6

  Alcocer, D B Luis ^a,c   Parra, C J Z ^c   Hernandez y HH ^b  

^a SECRETARÍA DE SALUD   (Mexico)

^b Clínica de Prevención del Riesgo Coronario

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTERIAL PRESSURE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DYSLIPIDEMIA; ECHOGRAPHY; EDITORIAL; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; RISK FACTOR; SITTING; SOCIAL PSYCHOLOGY;

EID: 77953271444     PISSN: 01882198     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. Mancia G, De Backer G, Doniczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
2. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptorblocker. N Engl J Med 2006; 354: 1685-1697.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
4. Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-1535.
5. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
6. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37: 250-254.
7. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme W, Scherhaug A. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure Data from the Carvedilol or metoprolol European Trial (COMET). Heart 2007.
8. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003; 361: 1149-1158.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.